Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Chih-Hsiang YuShiann-Tarng JouYing-Hui SuElane Coustan-SmithGang WuChao-Neng ChengMeng-Yao LuKai-Hsin LinKang-Hsi WuShu-Huey ChenFang-Liang HuangHsiu-Hao ChangJinn-Li WangHsiu-Ju YenMeng-Ju LiShu-Wei ChouWan-Ling HoYen-Lin LiuChia-Ching ChangZe-Shiang LinChien-Yu LinHsuan-Yu ChenYu-Ling NiDong-Tsamn LinShu-Wha LinJun J YangYen-Hsuan NiChing-Hong PuiSung-Liang YuYung-Li YangPublished in: Cancer (2022)
MRD-directed therapy improved the outcomes for pediatric ALL, especially standard-risk patients. Genomic analyses and MRD might be used together for risk-directed therapy of childhood ALL. Our work provides important data to inform the design of future clinical trials in Taiwan.
Keyphrases
- acute lymphoblastic leukemia
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- copy number
- early life
- childhood cancer
- peritoneal dialysis
- randomized controlled trial
- type diabetes
- stem cells
- electronic health record
- metabolic syndrome
- adipose tissue
- mesenchymal stem cells
- skeletal muscle
- young adults
- insulin resistance
- weight loss
- bone marrow
- phase ii
- open label
- patient reported
- glycemic control